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ABSTRACT
A fundamental concept in two-arm non-parametric survival analysis is the comparison of observed
versus expected numbers of events on one of the treatment arms (the choice of which arm is arbitrary),
where the expectation is taken assuming that the true survival curves in the two arms are identical.
This concept is at the heart of the counting-process theory that provides a rigorous basis for methods
such as the log-rank test. It is natural, therefore, to maintain this perspective when extending the
log-rank test to deal with non-proportional hazards, for example by considering a weighted sum of
the "observed - expected" terms, where larger weights are given to time periods where the hazard
ratio is expected to favour the experimental treatment. In doing so, however, one may stumble across
some rather subtle issues, related to the difficulty in ascribing a causal interpretation to hazard ratios,
that may lead to strange conclusions. An alternative approach is to view non-parametric survival
comparisons as permutation tests. With this perspective, one can easily improve on the efficiency of
the log-rank test, whilst thoroughly controlling the false positive rate. In particular, for the field of
immuno-oncology, where researchers often anticipate a delayed treatment effect, sample sizes could
be substantially reduced without loss of power.
1 Introduction
The emergence of checkpoint inhibitors in immuno-oncology has provoked much discussion about whether the log-rank
test (or Cox model) should continue to be used as a default primary analysis method in confirmatory studies, or whether
it is acceptable to use a method more tailored to non-proportional hazards [1–4]. The source of the controversy is the
clear tendency, when this kind of drug is compared with chemotherapy, for survival curves to remain more-or-less equal
for a number of months before they diverge. The log-rank test, while valid in terms of controlling the false positive rate,
may lose power under this scenario, and alternative methods, it is argued, can better distinguish whether an experimental
treatment is efficacious or not.
As a helpful guide for this discussion, multiple simulation studies have been completed that compare a wide array of
potential methods under a range of possible departures from proportional hazards [5–7]. The methods generally fall
into two categories: those derived from the Kaplan-Meier curves [8–11], and modifications to the log-rank test [12–15].
Scenarios extend well beyond the delayed-effect case just discussed, and also cover diminishing effects, crossing
survival curves, and cure-rate models. The favoured approaches emanating from this work [16] appear to be max-z-type
statistics [13] based on multiple weighted log-rank tests from the Fleming-Harrington-(ρ, γ) family [15]. However, the
response has not been universally positive. In particular, Freidlin & Korn [1] caution that such a test is not ready to be
used as the primary analysis for a confirmatory study. As part of their argument, they construct a scenario where the
experimental treatment is uniformly worse than control, yet the test would have a high chance of claiming a positive
result.
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The issue highlighted by Freidlin & Korn is partly a consequence of the way that we tend to view weighted log-rank
tests. Namely, as a weighted sum of observed versus expected numbers of events on one of the treatment arms (the
choice of which arm is arbitrary), where the expectation is taken assuming that the true survival curves in the two arms
are identical. The purpose of this article is to demonstrate that when one switches perspective, and instead views a
weighted log-rank test as a permutation test [17, 18], the deficiencies of certain choices of weighting become obvious,
and so does the way to fix it. Once this change of perspective has been achieved, the article will finish with a thorough
discussion of related issues: sample size calculation, treatment effect estimation, and interpretation of results.
2 "Observed vs. Expected" tests
2.1 Mantel’s test (1966)
What we now know as the "log-rank" test was introduced by Mantel [19]. Somewhat confusingly, its derivation has
nothing apparent to do with logarithms, nor ranks. Consider the toy data set in Table 1 (which we will use throughout).
Table 1: A toy data set, consisting of observations x and treatment labels z. A "+" suffix indicates a censored observation.
x z
2 0
6+ 0
7 1
8 0
9+ 1
11 0
13 1
17 0
22 1
23 1
24+ 0
30 1
The idea is to go through the ordered distinct event times tj (j = 1, . . . , k), constructing k 2x2 tables, such as Table 2.
Table 2: A 2x2 table describing the situation at event time tj .
Event = Y Event = N
Trt = 1 d1,j n1,j - d1,j n1,j
Trt = 0 d0,j n0,j - d0,j n0,j
dj nj - dj nj
Conditional on the margins of each 2x2 table, and assuming identical survival curves, the observed number of events on
the experimental treatment at event time tj , denoted by O1,j , follows a hypergeometric distribution, where the expected
number of events is E1,j = dj × n1j/nj , and the variance of O1,j is
V1,j =
n0,jn1,jdj(nj − dj)
n2j (nj − 1)
.
In our example, at the first event time, O1,1 = 0 and E1,1 = 1× 6/12 = 0.5. Continuing in this way we would produce
Table 3. Unconditionally, although the terms O1,j − E1,j are not independent, they are uncorrelated with mean 0 and
variance V1,j [20, p. 16]. It can be shown that, asymptotically,
U :=
∑
j
(O1,j − E1,j) ∼ N(0,
∑
j
V1,j). (1)
If the experimental treatment is beneficial, then the observed number of events on the experimental arm will tend to be
lower than what would be expected under an assumption of identical survival curves. One is hoping, therefore, to see
that U << 0 and that the one-sided p-value, p := Φ(U/
√
var(U)), is less than, e.g., α = 0.025. The sample size in
our toy example is too small to expect the normal approximation to be adequate. Nevertheless, for illustration purposes,
we would have U = −0.91, var(U) = 1.85 and p = 0.25.
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Table 3: Observed and expected numbers of events on the experimental arm at each event time for the toy data set in
Table 1
tj O1,j E1,j V1,j
2 0 0.50 0.25
7 1 0.60 0.24
8 0 0.56 0.25
11 0 0.57 0.24
13 1 0.67 0.22
17 0 0.60 0.24
22 1 0.75 0.19
23 1 0.67 0.22
30 1 1.00 0.00
2.2 Weighted log-rank tests
The form of the log-rank statistic (1), a sum of observed minus expected events, is straightforward and intuitive. But
why weight each event time equally when we anticipate a delayed treatment effect? It should be possible to find a more
powerful test by replacing U with a weighted sum of observed minus expected events,
UW :=
∑
j
wj (O1,j − E1,j) ∼ N(0,
∑
j
w2jV1,j).
The Fleming-Harrington-(0,1) test is a popular choice, where wj = 1 − Sˆ(tj−), i.e., one minus the Kaplan-Meier
estimate of the survival probability just before time tj , based on the pooled data from both treatment arms. The weight
for the first event is exactly 0, with the weights increasing towards 1. The intuition behind the test remains the same. If
the treatment is beneficial, we will tend to see fewer events on the treatment arm than would be expected assuming the
curves are identical. Now, however, we anticipate seeing O1,j < E1,j more frequently at later timepoints than at earlier
timepoints, and are upweighting these later events accordingly. We are hoping to increase the likelihood that UW << 0
and that pW < α, where pW := Φ(UW /
√
var(UW )).
2.3 Issues
To see the potential benefits, but also problems, with using the Fleming-Harrington-(0,1) test, a small simulation study
is helpful. Consider a randomized controlled trial where 500 patients are recruited to each treatment arm uniformly over
a 12 month period. Three scenarios are considered, described in Figure 1. Suppose that the trial ends 36 months after
the start of recruitment, at which point the event times of all surviving patients are censored. Results are shown in Table
4.
Table 4: Results from the simulation study described in the text and Figure 1. Based on 1000 repetitions.
Probability of claiming benefit
Scenario Log-rank Fleming-Harrington-(0,1)
(A) Delayed Effect 0.83 0.93
(B) Identical 0.02 0.03
(C) Worse than Control 0.00 0.07
For the delayed treatment effect scenario, the Fleming-Harrington-(0,1) test has much higher power than the log-rank
test. To put this difference in context, its relative efficiency is
100×
{
Φ−1(0.975) + Φ−1(0.93)
Φ−1(0.975) + Φ−1(0.83)
}2
= 139%.
This means that to achieve the same power as the Fleming-Harrington-(0,1) test, the sample size for the log-rank test
would need to be increased by about 40%. As dictated by the theory, both tests control the type 1 error rate when
survival curves are identical. The interesting scenario is (C), where the survival probability on the experimental arm
is lower than control at all timepoints. Intuitively, one might anticipate a very low chance of claiming pW < α. This
is indeed the case for the log-rank test, but for the Fleming-Harrington-(0,1) test we see that this probability is 7%.
The explanation is that despite a uniformly lower survival function, the hazard functions in this example are actually
crossing, and (weighted) log-rank tests are essentially a comparison of hazard functions. The Fleming-Harrington-(0,1)
3
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Figure 1: Scenarios used in the simulation study. (A) Control arm: exponential with median 15 months. Experimental
arm: two-piece exponential with rate log(2)/15 during months 0 to 6, and log(2)/21 thereafter. (B) Both arms
exponential with median 15 months. (C) Control arm: two-piece exponential with changepoint at 27 months with rates
log(2)/15 and log(2)/25. Experimental arm: three-piece exponential with changepoints at 7 and 27 months, and event
rates log(2)/11, log(2)/17 and log(2)/25.
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test gives low weight to early timepoints when the hazard is higher on the experimental arm than control, and high
weight to later timepoints when the hazard ratio favours the experimental arm. This observation is not new. It appears
in Fleming & Harrington’s book [21, p. 267]. More recently, Freidlin & Korn use this property to argue that the
Fleming-Harrington-(0,1) test is unsuitable for regulatory decision making. The idea that a comparison of hazard
functions might appear to favour an experimental treatment, despite there being no benefit, has been widely discussed
from an estimation and causal inference perspective [22–24].
3 Permutation tests
3.1 Wilcoxon’s rank-sum test (1945)
An alternative way to perform non-parametric survival comparisons is via permutation tests, building on Wilcoxon’s
(1945) rank-sum test [25]. Consider the data in Table 5, where (for the moment) the issue of censoring is ignored,
and we assume all values of x correspond to observed events. The idea is to assign a "score", denoted by a, to each
observation. In this case, we have given the longest survival time a score of 1, the second longest a score of 2, and so on.
The test statistic is simply the mean score on the experimental treatment minus the mean score on the control treatment.
To perform inference, one considers the data x as fixed, and the treatment labels z as random. In a randomized controlled
trial it is often reasonable to consider each possible permutation of the treatment labels as equally likely (for more
tailored randomization tests see, e.g., [26]). Therefore, one permutes the z very many times, each time re-calculating
the test statistic, as is shown in Table 5. The p-value is the proportion of times that the permutation test statistic is lower
than or equal to the observed test statistic. In this case, a¯1 − a¯0 = −1.16. Considering all treatment assignments as
equally likely, the proportion of times the permutation test statistic is less than or equal to −1.16 is about 0.15.
Table 5: How to perform a Wilcoxon rank-sum test when there are no censored observations.
x a z z∗1 z
∗
2 ... z
∗
p
2 12 0 0 0 1
6 11 0 0 1 0
7 10 1 0 0 0
8 9 0 1 0 0
9 8 1 1 1 1
11 7 0 1 0 1
13 6 1 0 1 1
17 5 0 1 0 1
22 4 1 0 1 0
23 3 1 0 1 0
24 2 0 1 0 0
30 1 1 1 1 1
a¯1 − a¯0 -1.16 -1.16 -1 0
3.2 Gehan’s test (1965)
How to extend the Wilcoxon rank-sum test to deal with censored observations? This question was tackled by Gehan [27].
His proposal is simple and intuitively appealing. The idea, as shown in Table 6, is to first order the pooled data, including
censored observations. Then, for each observation, count the number of patients that definitely have a longer survival
time, as well as the number that definitely have a shorter survival time. The score assigned to each observation is simply
the difference: #"better" - #"worse". The resulting scores are plotted in Figure 2(a). One can see that the scores remain
essentially a linear function of the ranks, where longer survival times get lower scores, and censored observations "slot
in". For example, an early censored observation gets the same score as an observed event somewhere towards the
middle of the distribution. The test procedure then proceeds in exactly the same way as for the Wilcoxon rank-sum
test. For our example, the difference in the average score (experimental - control) is -1.67. If one were to permute
the treatment labels very many times, recalculating the difference in average score each time, one would find that the
proportion of times that this difference is less than or equal to -1.67 is about 0.19. This is the p-value from the Gehan
test.
3.3 Log-rank test
Mantel’s (1966) test can also be expressed as a permutation test based on scores. The only difference is the way that
the scores, a, are assigned to the observations. A detailed derivation is provided in the Appendix. To summarise, one
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Table 6: How to perform Gehan’s (1965) test for the toy data set from Table 1.
x #"Better" #"Worse" a:= #"Better" - #"Worse" z z∗1 z
∗
2 ... z
∗
p
2 11 0 11 0 0 0 1
6+ 0 1 -1 0 0 1 0
7 9 1 8 1 0 0 0
8 8 2 6 0 1 0 0
9+ 0 3 -3 1 1 1 1
11 6 3 3 0 1 0 1
13 5 4 1 1 0 1 1
17 4 5 -1 0 1 0 1
22 3 6 -3 1 0 1 0
23 2 7 -5 1 0 1 0
24+ 0 8 -8 0 1 0 0
30 0 8 -8 1 1 1 1
a¯1 − a¯0 -1.67 -1.83 -3.17 0.5
first constructs the Nelson-Aalen estimate, S¯(t), of the survival curve based on the pooled data from both arms. An
observation that is censored at time xi receives a score of a = log S¯(xi). An observed event at time xi receives a
score of a = 1 + log S¯(xi). For our toy example, the resulting scores are shown in Figure 2(b). It is now immediately
apparent why it is called the "log-rank" test: the scores are a logarithmic function of the ranks. Inference follows the
same method as before. The test statistic is the mean score on the experimental arm minus the mean score on the control
arm. One then permutes the treatment labels very many times, each time calculating the difference in average scores,
to see how often this is less than or equal to the observed test statistic. In our case the p-value is 0.26. This closely
matches the p-value found in Section 2.
3.4 Optimal permutation-of-scores tests
We have just considered two different ways of assigning scores to (potentially censored) observations when comparing
survival on two treatment arms via a permutation test. One could, of course, think of many more ways to assign such
scores. Peto & Peto [28] showed that the log-rank scores are optimal under proportional hazards. Their proof can be
sketched out in three steps:
1. Firstly, they show that if one has independent observations x1, . . . , xn from any well-behaved parametric model f(θ),
with θ = θ0 for treatment 0, and θ = θ1 for treatment 1, then an asymptotically efficient test statistic for H0 : θ0 = θ1
is
n∑
i=1
I {patient i on trt 1} × ∂li(θ)
∂θ
∣∣∣∣
θ=θˆ
(2)
i.e., one considers the derivative of the log-likelihood contributions evaluated at the maximum likelihood estimate
(assuming there is a common parameter θ across both arms), and takes the sum of these contributions over one arm only.
2. Next they ask: what does proportional hazards look like for a parametric model? Using the well-known relationship
between the survival function and hazard function, S(t) = exp
(∫ t
0
h(u)du
)
, one can see that S(t; θ) := G(t)θ, where
G is an arbitrary basis survival curve, represents a proportional-hazards model. In this case,
∂li(θ)
∂θ
∣∣∣∣
θ=θˆ
=
1
θˆ
[
1 + log
{
G(xi)
θˆ
}]
(3)
when xi corresponds to an observed event, and
∂li(θ)
∂θ
∣∣∣∣
θ=θˆ
=
1
θˆ
log
{
G(xi)
θˆ
}
(4)
when xi corresponds to a censored event.
3. Finally, they replace the parametric maximum likelihood estimator S(t; θˆ) = G(t)θˆ with a non-parametric estimator,
for example the Nelson-Aalen estimator, S¯(t), in (3) and (4). Since S¯(t) and S(t; θˆ) will be asymptotically equivalent,
the test statistic (2) will remain asymptotically efficient. This is exactly the log-rank statistic (since the data is considered
fixed in a permutation test, the sum of scores on one arm only is an equivalent test statistic to taking the difference in
mean scores – see the Appendix).
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Figure 2: Scores from four permutation-of-scores tests applied to the toy data set from Table 1. To derive the ranks,
observations are ordered regardless of censoring. The observation corresponding to the largest x gets rank (1), etc.
Note how Peto & Peto derive the log-rank scores very directly. Also in 1972, Cox [29] published his famous proportional
hazards model, where, if treatment is the only covariate, the hazard function is λ0(t) on the control arm and λ0(t) exp(β)
on the experimental treatment arm. Inference proceeds via the partial likelihood for β,
L(β) = Πni=1
{
exp(β × I {patient i on trt 1})∑
l∈R(xi) exp(β × I {patient l on trt 1})
}δi
,
where δi = 1 if patient i = 1, ..., n has an observed event, and zero otherwise, where xi denotes the observation from
patient i, and R(xi) denotes the risk set at time xi. The efficient score statistic is
∂l(β)
∂β
∣∣∣∣
β=0
=
k∑
j=1
(O1,j − E1,j) ,
with O1,j and E1,j as defined above, and where the summation is now over the k event times. Once again, this is
exactly the log-rank statistic. Notice, however, that in contrast to Peto & Peto, what emerges from the Cox model is
Mantel’s "observed minus expected" form of the test statistic.
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4 Weighted log-rank tests as permutation tests
4.1 Fleming-Harrington (0,1) test
Given that the log-rank test can be viewed as both an observed-minus-expected test, and as a permutation test, it is
natural to ask if the same is true for the Fleming-Harrington-(0,1) test. Leton & Zuluaga [18] show that it is true for
every weighted log-rank test, and they provide formulas for calculating the corresponding scores (see Appendix). Figure
2(c) shows what the Fleming-Harrington-(0,1) scores look like when applied to our toy data set. Expressed in this way,
the issues that were apparent in the simulation study are now easy to explain. The scores (for observed events) are no
longer monotonically decreasing with time. This means, for example, that someone who dies at month 2 gets a lower,
i.e., "better", score than someone who dies at month 17. This point bears repeating. We are claiming a success when the
mean score on the experimental treatment is sufficiently lower than the mean score on control, yet the way that we
assign scores to observations gives lower scores to earlier deaths than later deaths.
4.2 Modestly-weighted log-rank test
When expressed as a permutation-of-scores test, we have seen that the Fleming-Harrington-(0,1) test statistic may
appear nonsensical, or at least inappropriate, for testing whether an experimental drug improves survival. Yet it clearly
has high power in delayed-effect scenarios. Is it possible to construct an alternative form of weighted log-rank test
that is powerful under delayed-effect scenarios but maintains a sensible interpretation when viewed as a permutation
test? This was the motivation behind the modestly-weighted log-rank test (MWLRT) of Magirr & Burman [30]. The
idea, depicted in Figure 2(d) for the toy example data, is to keep the scores fixed at 1 for all events up to a pre-specified
timepoint t∗. When viewed as a weighted observed-minus-expected test, this means that the weights start at around 1
for the first event, and are increasing up until time t∗. Beyond time t∗, however, we choose to keep the weights fixed at
the largest pre-t∗ value. When viewed again as a permutation test, this means that the scores are decreasing beyond
t∗. By using this procedure, we achieve the up-weighting of later event times, but also rule out the possibility of an
earlier death being given a better score than a later death. It turns out that one can achieve this pattern by using a weight
function:
wj = 1/max
{
Sˆ(tj−), Sˆ(t∗)
}
, (5)
where Sˆ(t) is the Kaplan-Meier estimate of the survival curve in the pooled data. This is highly convenient because
this weight function fits into the family studied by Fleming and Harrington [21, ch. 7], meaning that their asymptotic
distributional results apply. Implementing the MWLRT is therefore simple. It is entirely analogous to implementing the
Fleming-Harrington-(0,1) test. Note that (5) uses Sˆ(tj−) instead of the Sˆ(tj) used in [30]. This small change means
that the scores are now only approximately equal to 1 up to time t∗.
The MWLRT also has an appealing heuristic interpretation as a robust milestone (or landmark) analysis. A milestone
analysis compares estimated survival curves at a pre-specified timepoint, τ . This is a simple, intuitive, clinically-
interpretable summary measure. For non-censored data, one could construct a corresponding permutation-of-scores test
by, for example, assigning all survival times less than τ a score of 1, and all survival times greater than or equal to τ
a score of −1. One reason, however, for not choosing a milestone as the primary analysis method is the difficulty in
pre-specifying τ , and the loss in power from getting this choice wrong. To protect against a bad choice of τ , one could
think about pre-specifying a range of potential milestones, τ1, . . . , τm and using an average
1
m
m∑
i=1
Sˆ1(τi)− Sˆ0(τi)
as the test statistic. The corresponding permutation-of-scores test would assign scores to observations using the average
score across the m individual milestone tests, which would be similar in shape to the MWLRT scores, i.e., fixed at 1 for
a given period of time (up to τ1) before gradually declining. In this sense, the MWLRT can be thought of, heuristically,
as similar to a robust milestone analysis.
Finally, the MWLRT requires one to pre-specify a timepoint t∗. Given the multiple assumptions that go into designing
a survival trial, including recruitment rates, event rates and follow-up times, one could in theory choose t∗ to optimize
the power of the MWLRT (see [30]). However, as also shown in [30], and in contrast to a milestone analysis, the power
of the MWLRT is robust across a range of t∗. As a starting point, one could, for example, use the weight function
wj = 1/max
{
Sˆ(tj−), 0.5
}
,
which means that the weights are increasing until the survival estimate in the pooled data drops to 0.5. This will often
have good power in a delayed-effect scenario with reasonably mature data, for example, when there is enough follow-up
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for median survival times to be estimated from the Kaplan-Meier curves. Note that as t∗ →∞, the MWLRT weights
reduce to wj = 1/Sˆ(tj−), which Gray & Tsiatis [31] show are the optimal weights under a cure-rate model. As
discussed by Gray & Tsiatis, if the event rate is low, such that Sˆ(tj−) is never too far from 1, then there will be little
difference between this test and a standard log-rank test.
4.3 Simulation study (part 2)
We return to our simulation study, where we consider a randomized controlled trial with 500 patients recruited to
each treatment arm uniformly over a 12 month period, survival curves as shown in Figure 1, and administrative
censoring 36 months after the start of the study. The augmented results in Table 7 show that under the delayed-effect
scenario the MWLRT achieves much higher power than the standard log-rank test (although lower power than the
Fleming-Harrington-(0,1) test). To put this difference into context, the relative efficiency (when t∗ = 12) is
100×
{
Φ−1(0.975) + Φ−1(0.89)
Φ−1(0.975) + Φ−1(0.83)
}2
= 120%.
This means that to achieve the same power as the MWLRT, the sample size for the log-rank test would need to be
increased by about 20%. At the same time, the MWLRT guarantees that the probability of claiming benefit when the
experimental arm is uniformly worse than the control arm is below 2.5%. With an astutely chosen timepoint (τ = 27),
a milestone analysis also has high power under the delayed-effect scenario, but one can see the risk of power loss if a
suboptimal timepoint (τ = 21) is chosen. In contrast, the MWLRT maintains good power across a wide range of t∗. To
further elucidate the properties of the MWLRT, two further scenarios, shown in Figure 3, are added to the simulation
study, with results also given in Table 7. Under proportional hazards, the MWLRT maintains good power relative to the
standard log-rank test. However, if the assumption of a delayed effect is completely wrong, and there is a strong initial
effect that is diminishing over time, then the power of the MWLRT is much lower.
Table 7: Results from the simulation study described in the text and Figures 1 and 3. Based on 1000 repetitions
Probability of claiming benefit
Scenario Log-rank F-H-(0,1) MWLRT(12) MWLRT(24) Milestone(21) Milestone(27)
(A) Delayed Effect 0.83 0.93 0.89 0.91 0.78 0.87
(B) Identical 0.02 0.03 0.02 0.02 0.02 0.03
(C) Worse than Control 0.00 0.07 0.01 0.02 0.01 0.03
(D) Proportional Hazards 0.89 0.78 0.88 0.86 0.78 0.83
(E) Diminishing Effect 0.80 0.13 0.64 0.37 0.83 0.43
5 Discussion
5.1 From hypothesis testing to estimation
Throughout this paper, we have framed the discussion around hypothesis testing. The null hypothesis that is often
considered in survival analysis is H0 : S1(t) = S0(t) for all t. However, we have seen that this is rather a narrow view.
When testing an experimental drug in a confirmatory RCT, it is not sufficient to show that survival differs in some
unspecified way to the control arm. At the very least, one must demonstrate that there is a survival benefit at at least
some timepoints, and therefore H˜0 : S1(t) ≤ S0(t) for all t is a more appropriate null hypothesis. But rejecting H˜0 is
only a minimal requirement for drug approval. Beyond this, one of course needs to estimate the treatment effect in order
to judge its clinical relevance. In a well-designed confirmatory trial, serious forethought will have been given to this
issue, such that formal rejection of H˜0 will often coincide with an estimated effect size that is considered meaningful, as
is discussed below. This should never be taken for granted, though. Dangerous situations include subgroup analysis [32],
and early analysis of overall survival when a trial has been powered for progression-free survival. And "meaningful
effect" is of course subjective.
How is estimation typically handled? The predominant method is to plot Kaplan-Meier estimates of the survival curves
on the two treatments arms. This is an excellent way to judge clinical relevance. The effect size is shown on an absolute
scale, one sees the whole distribution, and it is unbiased in a single-stage (non-group-sequential) design provided that
censoring is non-informative (sequential testing and issues with informative censoring are out of scope for this paper).
It is not perfect, however, as it can be difficult to gauge the level of uncertainty surrounding the estimate, particularly in
the tail of the distribution [33].
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Figure 3: Additional scenarios used in the simulation study. (D) Control arm: exponential survival with median 15
months. Experimental arm: exponential survival with median 19 months. (E) Control arm: exponential survival with
median 15 months. Experimental arm: three-piece exponential with changepoints at 9 months and 18 months, with
rates log(2)/25, log(2)/18 and log(2)/13
In addition to Kaplan-Meier estimates, the estimated hazard ratio parameter from a Cox model is usually reported,
together with a confidence interval, regardless of whether the proportional hazards assumption appears reasonable or
not. What does this number really mean? As shown by Berry et al. [34], the Peto hazard ratio estimate,
θˆ = exp
(∑
j O1,j − E1,j∑
j V1,j
)
, (6)
will be close to the Cox model estimate under certain (often reasonable) assumptions. One can express (6) as a weighted
geometric mean,
θˆ = exp
(∑
k Ik log θˆk∑
k Ik
)
(7)
where θˆk is the estimate of the hazard ratio in a time interval (τk−1, τk] for some 0 = τ0 < τ1 < · · · < τm, and
Ik =
∑
tj∈(τk−1,τk] V1j is approximately equal to the number of observed events in (τk−1, τk] divided by 4 (assuming
1:1 randomization). If the hazard ratio changes over time, the estimand targeted by θˆ becomes a weighted average of the
hazard ratio function with weights dictated by the number of observed events in each time period. In other words, the
estimand is a function of both the time-to-event distributions and the censoring distributions, the latter being dictated
chiefly by the recruitment rate and follow-up time [35, 36]. Strictly speaking, this is an absurd estimand for judging
clinical relevance. Why should clinical relevance depend on the recruitment rate? In practice, of course, the hazard ratio
parameter is used in a more limited sense. For example, an estimated hazard ratio of 0.5 with 95% confidence interval
(0.25,1) is associated with the same p-value as an estimated hazard ratio of 0.95 with 95% confidence interval (0.9, 1).
In the first case, we would say that we have a large relative effect that is imprecisely estimated, whereas in the second
case we have a small, but precisely estimated, relative effect. This type of qualitative conclusion will often be valid
even under non-proportional hazards (though perhaps not when one has an extreme case of crossing survival curves).
Obviously, regardless of proportional hazards, the hazard ratio parameter says nothing about absolute treatment effects.
A hazard ratio of 0.8 means something very different when median survival is 2 months compared to when it is 5 years.
It should by now be clear that using the MWLRT instead of a standard log-rank test does not risk introducing a
disconnect between hypothesis testing and interpretation of effect size. Such a disconnect already exists. And this is
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a good thing. Relying on the point estimate and confidence interval of the hazard ratio parameter from a Cox model
would be inappropriate.
5.2 Sample size considerations
How do sample size calculations proceed when one anticipates a delayed-effect scenario? To give a flavour, one might
start out by ignoring the delayed effect, and using very simple working assumptions: exponential survival distributions,
a median survival of µ0 months on control, and a desire for high power should median survival on control be µ1 months.
Assuming a standard log-rank statistic, for 1:1 randomization, the required number of events would be
ne = 4
(
Φ−1(0.9) + Φ−1(0.975)
− log(µ0/µ1)
)2
,
assuming a one-sided significance level of 2.5% and power 90%, say. In this case, a hazard ratio point estimate of
θˆ∗ = exp
{
Φ−1(0.025)
√
4
ne
}
would just about achieve statistical significance. Notice that there is a trade-off here. One needs large ne to have
sufficient power, but making ne too large means θˆ∗ goes to 1, i.e., there is a possibility of getting a significant but
not clinically meaningful result. These two opposing forces should lead to a sensible ne. The next step would be to
convert the required number of events into a sample size, based on available knowledge regarding recruitment rates
and maximum potential follow-up time. This step could be more or less sophisticated, but it is standard practice, and
software is widely available.
If the working assumption is considered implausible, and there is a strong belief that the hazard rates on the two arms
will be similar for the first 3 or 4 months, for example, before diverging, then the next step would probably be to simulate
the trial, based on the sample size derived from the working assumptions, but using the more realistic time-to-event
distributions. The simulated power is likely to be less than 90%, and one would need to tweak either the sample size or
follow-up time to get it back up there. Perhaps a range of options would be considered. Note that this step is already a
complex undertaking. If the MWLRT is used instead of the log-rank statistic, the only thing that changes is the test
procedure used in the simulation study. The size of the task is essentially the same.
5.3 Crossing survival curves
If we lived in a world where survival distributions on the two arms were guaranteed to either belong to H˜ , i.e.,
S1(t) ≤ S0(t) for all t, or to have S1(t) ≥ S0(t) for all t (with strict superiority at least for some t), then there would
perhaps be little controversy in choosing between a log-rank test, MWLRT, or a milestone as the primary analysis
method, based purely on power considerations. Sometimes, however, the truth will be that S1(t) < S0(t) for some t,
and S1(t) > S0(t) for other t. What do we want to happen in such situations? Do we want a test that is powerful in
terms of picking out that S1(t) > S0(t) for at least some t? Or do we see this as undesirable, and hence are looking
for a conservative test that somehow balances out the different time periods to give a null result? This is impossible
to answer in general, because it depends on how we trade off the value of short-term versus long-term survival. One
thing that can be said, however, is that the standard log-rank test is by no means a neutral default. Contrary to what
is sometimes claimed [1], the standard log-rank statistic does not weight all parts of the survival curves equally. We
have seen in (7) that it weights the survival curves based on how many events are observed in each time period. For
example, with heavy early censoring, most events would happen in the early part of the curves, such that a fleeting early
difference might be exaggerated. The point here is not that the standard log-rank test is a bad choice. Rather, no test
will be uniformly most sensible under crossing survival curves. This underlines the importance of carefully assessing
treatment effect size, in particular, via the Kaplan-Meier estimates.
5.4 Concluding remarks
In 2019, Freidlin & Korn wrote a commentary in the Journal of Clinical Oncology entitled "Methods for accommodating
non-proportional hazards in clinical trials: ready for the primary analysis?" Arguably, at least in the case of weighted
log-rank statistics, the answer to that question was indeed "no". When viewed as a permutation-of-scores test, the
Fleming-Harrington-(0,1) statistic assigns better scores to worse outcomes. In the context of the primary analysis of a
confirmatory clinical trial testing whether experimental treatment improves survival, this is a fundamental weakness.
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Many recently proposed methods, for example the "max-combo" test [5, 16], incorporate the Fleming-Harrington-(0,1)
test as a component, and therefore inherit this weakness. Fortunately, however, the permutation-of-scores perspective
also shows us how to rectify this issue. The MWLRT has the key property that if survival on the experimental drug is
truly lower (or equal) to survival on control at all timepoints, then the probability of claiming a statistically significant
improvement is less than 2.5% (assuming a conventional threshold is applied). In addition, for many common scenarios
in immuno-oncology, sample size can be reduced by 10 – 20%, compared to using a standard log-rank test, without
losing power. On top of power and false-positive-rate considerations, it is also very simple to implement, comes with
rigorous asymptotic results, and has an appealing heuristic interpretation as a robust milestone analysis. It therefore
deserves serious consideration as the primary analysis method in confirmatory trials. Interpretation of treatment effect
size does not come for free. But it never does in survival analysis.
Appendix
Following Leton & Zuluaga [18], and letting l1,j and l0,j denote the number of patients censored on the test treatment
and control treatment, respectively, during [ tj , tj+1) ,
U :=
k∑
j=1
(
O1,j −Oj n1,j
nj
)
=
k∑
j=1
O1,j −
k∑
j=1
Oj
nj
× n1,j
=
k∑
j=1
O1,j −
k∑
j=1
Oj
nj
×
k∑
i=j
(O1,i + l1,i)
=
k∑
j=1
O1,j −
k∑
j=1
(O1,j + l1,j)×
j∑
i=1
Oi
ni
=
k∑
j=1
O1,j
(
1−
j∑
i=1
Oi
ni
)
+
k∑
j=1
l1,j
(
−
j∑
i=1
Oi
ni
)
=
k∑
j=1
O1,j ×
{
1 + log(S¯NA(tj))
}
+
k∑
j=1
l1,j × log(S¯NA(tj)).
Ranking the observations, regardless of censoring, x(n) ≤ x(n−1) ≤ · · · ≤ x(2) ≤ x(1), and denoting the corresponding
treatment assignments as, z(n) ≤ z(n−1) ≤ · · · ≤ z(2) ≤ z(1), one can write U =
∑n
i=1 I
{
z(i) = 1
}
a(i), where
a(i) = I
{
x(i) not censored
}
+ log(S¯NA(x(i))).
Therefore one can perform the log-rank test by permuting treatment labels very many times, each time recalculating U ,
and counting the proportion of times that the it is less than or equal to the original value. Note, however, that instead of
using U one could also use
U˜ =
∑n
i=1 I
{
z(i) = 1
}
a(i)∑n
i=1 I
{
z(i) = 1
} − ∑ni=1 I{z(i) = 0} a(i)∑n
i=1 I
{
z(i) = 0
} ,
as the test statistic in the permutation test, as U and U˜ are equivalent up to a (positive) scale and shift transformation,
i.e.,
U˜ =
n∑n
i=1 I
{
z(i) = 1
}∑n
i=1 I
{
z(i) = 0
} × U − ∑ni=1 a(i)∑ni=1 I{z(i) = 1}∑n
i=1 I
{
z(i) = 1
}∑n
i=1 I
{
z(i) = 0
} .
In general, when we introduce weights:
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UW :=
k∑
j=1
wj
(
O1,j −Oj n1,j
nj
)
=
k∑
j=1
wjO1,j −
k∑
j=1
wj
Oj
nj
× n1,j
=
k∑
j=1
wjO1,j −
k∑
j=1
wj
Oj
nj
×
k∑
i=j
(O1,i + l1,i)
=
k∑
j=1
wjO1,j −
k∑
j=1
(O1,j + l1,j)×
j∑
i=1
wi
Oi
ni
=
k∑
j=1
O1,j
(
wj −
j∑
i=1
wi
Oi
ni
)
+
k∑
j=1
l1,j
(
−
j∑
i=1
wi
Oi
ni
)
.
This means that an observed event at time tj is given a score of a = wj −
∑j
i=1 wi
Oi
ni
, and an observation censored
during [ tj , tj+1) is given a score of a = −
∑j
i=1 wi
Oi
ni
.
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